Biocon plans India listing for Syngene in R&D funding move

Biocon plans to list its Syngene International research subsidiary on the India stock market by launching a $160 million initial public offering. With money in Syngene's pockets, Biocon then plans to sell 10% of its holdings to raise about $95 million for its own research.

The intentions were revealed in a filing with the Securities and Exchange Board of India. Subject to approval, Biocon is aiming for a listing as early as July. Earlier this year, when Biocon sold another 10% stake in the research unit, Syngene was valued at about $600 million.

Syngene also offers services for drug discovery and development across several medical fields.

- here's the story from The Hindu
- read more from Times of India
- get FierceCRO's take